Kemwell receives Health Canada approval for its Oral Solids facility in Bangalore2012-07-17 09:12
Kemwell Biopharma has received approval from Health Canada to manufacture and supply oral solid dosage products from its facility in Bangalore to the Canadian market. The facility has been in operation since 2008 and received its first EMA approval in 2008. Speaking on the occasion, Anurag Bagaria, Chairman and Managing Director, said “this approval will give access to Kemwell’s current and prospective customers to the growing Canadian market. The approval also backs Kemwell’s commitment to becoming a global partner and providing high quality products”.
The state-of-the-art unit is currently equipped to manufacture and package 2 billion units and this can be further expanded to produce 5 billion units per annum. Kemwell already produces a wide range of products including un-coated, coated, effervescent tablets and capsules for the European, New Zealand, Australian markets and is awaiting its first USFDA Audit later this year.
Kemwell Biopharma Pvt Ltd with its head office in Bangalore, India is a pure play contract development and manufacturing company. The company manufactures pharmaceuticals for some of the world’s top pharmaceutical companies, including GlaxoSmithKline, Bayer, Johnson & Johnson, Novartis and Pfizer. Kemwell Biopharma Pvt Ltd is one of India’s largest contract manufacturers of pharmaceuticals with over 30 years’ experience. The company employs more than 1000 employees worldwide and has seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets.
Read more about Kemwell on www.kemwellbiopharma.com